Restoring mutant P53 function in tnbc using polymacrocyclic peptides
Active Project Grant Awarded Last action
- Award ID
- HT9425261E422
- Recipient
-
Sethera Therapeutics, Inc. UEI UPXWQBWXK1B9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $231,518
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 7% complete
- Place of performance
- Salt Lake City, UT 84101, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded $231,518 to Sethera Therapeutics, Inc. on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research on restoring mutant p53 function in triple-negative breast cancer using polymacrocyclic peptides. Performance occurs in Salt Lake City, Utah through July 31, 2029. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative research and to investigate medical solutions for the battlefield.
Quick answers
Who received award HT9425261E422?
HT9425261E422 was awarded to Sethera Therapeutics, Inc. by Defense Health Agency (Department of Defense) on August 1, 2026.
How much is award HT9425261E422 worth?
$231,518 has been obligated on HT9425261E422.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award